Jacob Garcia

Hospital General Universitario de Elche — Spain

Medicine · Health Sciences

21h-index3.7kcitations72works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(33), Neutropenia and Cancer Infections(18), Biosimilars and Bioanalytical Methods(11), Blood disorders and treatments(10), Lymphoma Diagnosis and Treatment(8)

Publications70 total

A Phase 1, Multicenter, Open-Label Study of UB-VV111 in Combination with Rapamycin in Relapsed/Refractory CD19+ B-Cell Malignancies
Blood·2024· 6 cited
233 Early experience on ENLIGHTen-01: a phase 1 study of FITC-E2 CAR-T cells with CAR adaptor molecule UB-TT170 for relapsed/refractory osteosarcoma
Regular and Young Investigator Award Abstracts·2024Open Access
AB0570 EFFECTS OF REGULAR YOGA AND MEDITATION PRACTICE ON PAIN AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Annals of the Rheumatic Diseases·2024
ENLIGHten-01: A phase 1 study of fluorescein-specific (FITC-E2)-CAR T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma.
Journal of Clinical Oncology·2023· 4 cited
23P Prognostic value of tumor-infiltrating lymphocytes (TILs) and soluble immune checkpoints in early triple-negative breast cancer (TNBC)
ESMO Open·2023Open Access
17P Prognostic and predictive non-invasive biomarkers in early triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT)
ESMO Open·2023Open Access
Abstract CT137: ENLIGHTen-01: a phase 1 study of fluorescein-specific (FITC-E2)-car T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma
Cancer Research·2023
Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma
PharmacoEconomics - Open·2022· 13 citedOpen Access
205P Immunomodulation in early triple-negative breast cancer (TNBC): Analysis of soluble markers as predictive biomarkers to neoadjuvant chemotherapy in TNBC
Annals of Oncology·2021
Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care
Advances in Therapy·2021· 31 citedOpen Access
FEMTOSECOND PUMP-PROBE SPECTROSCOPY OF NEUTRAL Ni AND Cr OXIDE CLUSTERS
Proceedings of the 2021 International Symposium on Molecular Spectroscopy·2021Open Access
Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1
Advances in Therapy·2021· 23 citedOpen Access
Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma
Blood Advances·2021· 36 citedOpen Access
Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial
Blood Advances·2021· 30 citedOpen Access
Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials
Blood·2020· 3 cited
Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001
Blood·2020· 63 cited
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
The Lancet·2020· 2.2k cited
Ultrafast Pump-Probe Spectroscopy of Finite-Sized Neutral Iron Oxide Clusters
2020· 4 citedOpen Access
<p>Sternoclavicular Joint Instability: Symptoms, Diagnosis And Management</p>
Orthopedic Research and Reviews·2020· 20 citedOpen Access
Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Journal of Clinical Oncology·2020
page 1 of 4Next →

Frequent Co-authors

David G. Maloney(18), Jeremy S. Abramson(16), Tanya Siddiqi(16), Matthew A. Lunning(13), Christine Dehner(13), Leo I. Gordon(12), Michael Wang(12), Jon Arnason(12), Tina Albertson(12), Maria Lia Palomba(11), Benhuai Xie(10), D. Li(8), Yeonhee Kim(7), Phuong K. Morrow(7), Andres Forero‐Torres(6), Gary H. Lyman(6), Maureen Reiner(6), Monika P. Jun(6), Charalambos Andreadis(5), Scott R. Solomon(5)